09/09/2026
๐ฃ๐ต๐ฎ๐ฟ๐บ๐ฎ๐ฐ๐ฒ๐๐๐ถ๐ฐ๐ฎ๐น ๐ค๐๐ฎ๐น๐ถ๐๐ ๐จ๐ฝ๐ฑ๐ฎ๐๐ฒ | ๐๐๐ฆ๐๐ข ๐ก๐ฆ๐ค ๐๐น๐ฒ๐ฟ๐ ๐
Quality compliance remains fundamental to ensuring the safety, efficacy, and reliability of pharmaceutical products.
As per the CDSCO NSQ Alert, a batch of Pantoprazole Tablets IP (Batch PEP5001) manufactured by Finecure Pharmaceuticals was identified as Not of Standard Quality (NSQ) due to non-compliance with the prescribed IP dissolution requirements.
The reported finding indicated that 3 out of 6 tablets were below Qโ25%, highlighting the importance of robust dissolution testing and continuous quality monitoring throughout the pharmaceutical product lifecycle.
At Choksi Laboratories Limited, we remain committed to supporting pharmaceutical quality through reliable analytical testing and regulatory-focused laboratory services.
Precision in Testing. Confidence in Results.
๐ www.choksilab.in
โ [email protected]
Source: CDSCO NSQ Alerts